Literature DB >> 26844447

Aedes aegypti anti-salivary gland antibody concentration and dengue virus exposure history in healthy individuals living in an endemic area in Colombia.

Berlín Londoño-Rentería1, Jenny C Cárdenas2, Jennifer E Giovanni3, Lucio Cárdenas1, Paloma Villamizar1, Jennifer Rolón1, Daniel M Chisenhall3, Rebecca C Christofferson3, Daisy J Carvajal1, Omar G Pérez1, Dawn M Wesson4, Christopher N Mores5.   

Abstract

INTRODUCTION: Mosquito salivary proteins are able to induce an antibody response that reflects the level of human-vector contact. IgG antibodies against dengue virus (DENV-IgG) are indicators of previous exposure. The risk of DENV transmission is not only associated to mosquito or dengue factors, but also to socioeconomic factors that may play an important role in the disease epidemiology.
OBJECTIVE: To determine the effect of the presence of Aedes aegypti mosquitos in different stages in households and the history of dengue exposure on vector-human contact determined by the level of anti-salivary protein antibodies in people living in a Colombian endemic area.
MATERIALS AND METHODS: A pilot study of 58 households and 55 human subjects was conducted in Norte de Santander, Colombia. A questionnaire for socioeconomic factors was administered and houses were examined for the presence of Ae. aegypti specimens in the aquatic stages. The level of DENV-IgG antibodies (DENV-IgG), in addition to IgG and IgM anti- Ae. aegypti salivary gland extract (SGE) antibodies (SGE-IgG, SGE-IgM) were evaluated by ELISA using blood collected in filter paper.
RESULTS: We found a significant higher level of SGE-IgG antibodies in subjects living in houses with Ae. aegypti in aquatic stages. We also found a higher concentration of SGE-IgG antibodies in people exposed to DENV, a positive correlation between IgM-SGE and IgG-DENV and a negative correlation with IgG-SGE.
CONCLUSION: Anti-salivary proteins antibodies are consistent with the presence of Ae. aegypti aquatic stages inside houses and DENV-IgG antibodies concentrations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26844447     DOI: 10.7705/biomedica.v35i4.2530

Source DB:  PubMed          Journal:  Biomedica        ISSN: 0120-4157            Impact factor:   0.935


  11 in total

1.  A prospective cohort study to assess seroprevalence, incidence, knowledge, attitudes and practices, willingness to pay for vaccine and related risk factors in dengue in a high incidence setting.

Authors:  Ruth Aralí Martínez-Vega; Alfonso J Rodriguez-Morales; Yalil Tomás Bracho-Churio; Mirley Enith Castro-Salas; Fredy Galvis-Ovallos; Ronald Giovanny Díaz-Quijano; María Lucrecia Luna-González; Jaime E Castellanos; José Ramos-Castañeda; Fredi Alexander Diaz-Quijano
Journal:  BMC Infect Dis       Date:  2016-11-25       Impact factor: 3.090

2.  Cost of illness and program of dengue: A systematic review.

Authors:  Luana Nice da Silva Oliveira; Alexander Itria; Erika Coutinho Lima
Journal:  PLoS One       Date:  2019-02-20       Impact factor: 3.240

3.  Differential Tick Salivary Protein Profiles and Human Immune Responses to Lone Star Ticks (Amblyomma americanum) From the Wild vs. a Laboratory Colony.

Authors:  L Paulina Maldonado-Ruiz; Lidia Montenegro-Cadena; Brittany Blattner; Sapna Menghwar; Ludek Zurek; Berlin Londono-Renteria
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

4.  Serosurvey of Human Antibodies Recognizing Aedes aegypti D7 Salivary Proteins in Colombia.

Authors:  Berlin L Londono-Renteria; Heman Shakeri; Paula Rozo-Lopez; Michael J Conway; Natasha Duggan; Majid Jaberi-Douraki; Tonya M Colpitts
Journal:  Front Public Health       Date:  2018-05-18

5.  Current vector research challenges in the greater Mekong subregion for dengue, Malaria, and Other Vector-Borne Diseases: A report from a multisectoral workshop March 2019.

Authors:  Rebecca C Christofferson; Daniel M Parker; Hans J Overgaard; Jeffrey Hii; Gregor Devine; Bruce A Wilcox; Vu Sinh Nam; Sazaly Abubakar; Sebastien Boyer; Kobporn Boonnak; Stephen S Whitehead; Rekol Huy; Leang Rithea; Tho Sochantha; Thomas E Wellems; Jesus G Valenzuela; Jessica E Manning
Journal:  PLoS Negl Trop Dis       Date:  2020-07-30

Review 6.  New Immuno-Epidemiological Biomarker of Human Exposure to Aedes Vector Bites: From Concept to Applications.

Authors:  André B Sagna; Mabo C Yobo; Emmanuel Elanga Ndille; Franck Remoue
Journal:  Trop Med Infect Dis       Date:  2018-08-01

7.  Specific human antibody responses to Aedes aegypti and Aedes polynesiensis saliva: A new epidemiological tool to assess human exposure to disease vectors in the Pacific.

Authors:  Françoise Mathieu-Daudé; Aurore Claverie; Catherine Plichart; Denis Boulanger; Fingani A Mphande; Hervé C Bossin
Journal:  PLoS Negl Trop Dis       Date:  2018-07-24

8.  IgG1 and IgG4 antibodies against Aedes aegypti salivary proteins and risk for dengue infections.

Authors:  Jenny C Cardenas; Papa M Drame; Karina A Luque-Burgos; Juan D Berrio; Elsi Entrena-Mutis; María U González; Daisy J Carvajal; Lady Y Gutiérrez-Silva; Lucio D Cardenas; Tonya M Colpitts; Christopher N Mores; Berlin Londono-Renteria
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

9.  Antibody Responses Against Anopheles darlingi Immunogenic Peptides in Plasmodium Infected Humans.

Authors:  Berlin Londono-Renteria; Jehidys Montiel; Eric Calvo; Alberto Tobón-Castaño; Hugo O Valdivia; Karin Escobedo-Vargas; Luz Romero; Maria Bosantes; Michael L Fisher; Michael J Conway; Gissella M Vásquez; Audrey E Lenhart
Journal:  Front Cell Infect Microbiol       Date:  2020-08-31       Impact factor: 5.293

10.  Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.

Authors:  Humberto Reynales; Gabriel Carrasquilla; Betzana Zambrano; Margarita Cortés S; Tifany Machabert; Jin Jing; Sophie Pallardy; Owen Haney; Martha Faccini; Juliana Quintero; Fernando Noriega
Journal:  Pediatr Infect Dis J       Date:  2020-04       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.